Vaishali Pharma Limited (VAISHALI) - Net Assets
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) has net assets worth Rs673.82 Million INR (≈ $7.29 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs1.22 Billion ≈ $13.19 Million USD) and total liabilities (Rs545.40 Million ≈ $5.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vaishali Pharma Limited (VAISHALI) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs673.82 Million |
| % of Total Assets | 55.27% |
| Annual Growth Rate | 30.05% |
| 5-Year Change | 189.56% |
| 10-Year Change | 1895.13% |
| Growth Volatility | 116.55 |
Vaishali Pharma Limited - Net Assets Trend (2013–2025)
This chart illustrates how Vaishali Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore VAISHALI asset base for the complete picture of this company's asset base.
Annual Net Assets for Vaishali Pharma Limited (2013–2025)
The table below shows the annual net assets of Vaishali Pharma Limited from 2013 to 2025. For live valuation and market cap data, see Vaishali Pharma Limited market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs649.16 Million ≈ $7.02 Million |
+51.53% |
| 2024-03-31 | Rs428.39 Million ≈ $4.63 Million |
+5.69% |
| 2023-03-31 | Rs405.31 Million ≈ $4.38 Million |
+53.79% |
| 2022-03-31 | Rs263.54 Million ≈ $2.85 Million |
+17.56% |
| 2021-03-31 | Rs224.19 Million ≈ $2.42 Million |
+4.85% |
| 2020-03-31 | Rs213.81 Million ≈ $2.31 Million |
-0.08% |
| 2019-03-31 | Rs213.99 Million ≈ $2.31 Million |
+3.87% |
| 2018-03-31 | Rs206.02 Million ≈ $2.23 Million |
+432.55% |
| 2017-03-31 | Rs38.69 Million ≈ $418.36K |
+18.89% |
| 2016-03-31 | Rs32.54 Million ≈ $351.88K |
+0.58% |
| 2015-03-31 | Rs32.35 Million ≈ $349.85K |
+5.25% |
| 2014-03-31 | Rs30.74 Million ≈ $332.40K |
+10.84% |
| 2013-03-31 | Rs27.73 Million ≈ $299.89K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vaishali Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 592.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs157.29 Million | 24.23% |
| Common Stock | Rs260.92 Million | 40.19% |
| Other Comprehensive Income | Rs1.84 Million | 0.28% |
| Other Components | Rs229.11 Million | 35.29% |
| Total Equity | Rs649.16 Million | 100.00% |
Vaishali Pharma Limited Competitors by Market Cap
The table below lists competitors of Vaishali Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AB Panevezio Statybos Trestas
STU:YK3
|
$10.74 Million |
|
HOV Services Limited
NSE:HOVS
|
$10.75 Million |
|
Arbor Metals Corp
V:ABR
|
$10.75 Million |
|
Motio Ltd
AU:MXO
|
$10.75 Million |
|
SIXTY NORTH GOLD MIN.LTD.
F:2F40
|
$10.74 Million |
|
Scorpion Minerals Ltd
AU:SCN
|
$10.73 Million |
|
New Nordic Healthbrands AB (publ)
ST:NNH
|
$10.73 Million |
|
Jatcorp Ltd
AU:JAT
|
$10.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaishali Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 428,394,000 to 649,161,000, a change of 220,767,000 (51.5%).
- Net income of 8,173,000 contributed positively to equity growth.
- Share repurchases of 212,564,000 reduced equity.
- New share issuances of 212,564,000 increased equity.
- Other comprehensive income decreased equity by 319,361,001.
- Other factors increased equity by 531,955,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs8.17 Million | +1.26% |
| Share Repurchases | Rs212.56 Million | -32.74% |
| Share Issuances | Rs212.56 Million | +32.74% |
| Other Comprehensive Income | Rs-319.36 Million | -49.2% |
| Other Changes | Rs531.96 Million | +81.95% |
| Total Change | Rs- | 51.53% |
Book Value vs Market Value Analysis
This analysis compares Vaishali Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.89x to 0.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | Rs2.63 | Rs7.61 | x |
| 2014-03-31 | Rs2.91 | Rs7.61 | x |
| 2015-03-31 | Rs3.07 | Rs7.61 | x |
| 2016-03-31 | Rs3.09 | Rs7.61 | x |
| 2017-03-31 | Rs3.67 | Rs7.61 | x |
| 2018-03-31 | Rs22.76 | Rs7.61 | x |
| 2019-03-31 | Rs20.29 | Rs7.61 | x |
| 2020-03-31 | Rs20.27 | Rs7.61 | x |
| 2021-03-31 | Rs21.26 | Rs7.61 | x |
| 2022-03-31 | Rs24.99 | Rs7.61 | x |
| 2023-03-31 | Rs36.28 | Rs7.61 | x |
| 2024-03-31 | Rs37.21 | Rs7.61 | x |
| 2025-03-31 | Rs44.10 | Rs7.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaishali Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.83%
- • Asset Turnover: 0.90x
- • Equity Multiplier: 1.69x
- Recent ROE (1.26%) is below the historical average (7.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 21.64% | 0.51% | 2.45x | 17.52x | Rs3.23 Million |
| 2014 | 9.78% | 0.25% | 2.26x | 17.38x | Rs-68.60K |
| 2015 | 4.99% | 0.17% | 2.06x | 14.16x | Rs-1.62 Million |
| 2016 | -0.93% | -0.05% | 1.34x | 15.30x | Rs-3.56 Million |
| 2017 | 17.16% | 1.00% | 1.48x | 11.54x | Rs2.77 Million |
| 2018 | 3.87% | 1.22% | 1.02x | 3.12x | Rs-12.63 Million |
| 2019 | 3.33% | 0.98% | 1.05x | 3.21x | Rs-14.26 Million |
| 2020 | 0.15% | 0.06% | 0.88x | 3.10x | Rs-21.05 Million |
| 2021 | 4.67% | 1.95% | 0.62x | 3.84x | Rs-11.96 Million |
| 2022 | 15.27% | 5.31% | 0.93x | 3.10x | Rs13.88 Million |
| 2023 | 16.29% | 9.48% | 0.88x | 1.95x | Rs25.50 Million |
| 2024 | 1.68% | 0.83% | 1.08x | 1.87x | Rs-35.65 Million |
| 2025 | 1.26% | 0.83% | 0.90x | 1.69x | Rs-56.74 Million |
Industry Comparison
This section compares Vaishali Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaishali Pharma Limited (VAISHALI) | Rs673.82 Million | 21.64% | 0.81x | $10.74 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more